Andrew Wechsler, M.D., Joins Estech as Medical Director
SAN RAMON, Calif.-(Business Wire)-September 22, 2009 - Endoscopic Technologies, Inc. (d.b.a. Estech®), a leading provider of minimally invasive cardiac surgery devices and disposables, today announced the appointment of Andrew S. Wechsler, M.D., as its medical director. Dr. Wechsler will chair the Estech Medical Advisory Board, which provides guidance on the company’s clinical research, medical education and product development efforts. He will also support the company’s clinical awareness and advocacy initiatives. Dr. Wechsler will continue his role as Stanley K. Brockman professor and chair, Department of Cardiothoracic Surgery, Drexel University College of Medicine.
“We are honored to appoint a medical director of Dr. Wechsler’s caliber,” said John Pavlidis, Estech’s president and chief executive officer. “With his professional stature and his distinguished accomplishments as a clinical investigator, Dr. Wechsler will serve as a significant resource for our continued advances in the field of minimally invasive cardiac surgery. Additionally, his vast experience as a clinician, educator and journal editor will enable him to enhance Estech’s ongoing ability to effectively address the challenges that cardiac surgeons face every day.”
Dr. Wechsler received his medical degree at State University of New York Downstate and completed his cardiac surgery residency at Duke University. He has served as a council member of the American Association for Thoracic Surgery (AATS), the Society of Thoracic Surgeons and the European Association for Cardio-Thoracic Surgery. Dr. Wechsler has been widely recognized for his contributions to the field of cardiac surgery, most recently as the recipient of the prestigious AATS Scientific Achievement Award. From 1999 to 2007, he was editor of the Journal of Thoracic and Cardiovascular Surgery, where he now serves as editor emeritus.
“As a long-time user of Estech’s products for minimally invasive surgery, I am impressed with the company’s management, product portfolio and its dedication to the needs of the cardiothoracic surgeon,” said Dr. Wechsler. “I look forward to supporting the company’s endeavors to continue to develop innovative solutions that help cardiac surgeons and improve patient outcomes.”
About Estech
Estech develops and markets a broad portfolio of innovative medical devices and disposables that enable cardiac surgeons worldwide to perform a variety of traditional and minimally invasive surgical procedures. Estech is one of only a few medical device companies that focuses solely on cardiac surgeons. The company markets its products in the United States through its direct sales force, and in more than 30 countries internationally through its distributor network. The company’s products target three cardiac surgery disciplines: surgical RF ablation, valve replacement or repair, and coronary artery bypass grafting. Estech is privately held and backed by a number of leading life sciences venture capital firms based in Silicon Valley and Europe.
Estech’s ablation products are protected by a broad portfolio of over 90 issued patents including, but not limited to: U.S. Patent Nos. 7,115,122, 6,830,576, 6,579,288, 6,241,754, 5,651,780, and 5,575,772. For more information, visit www.estech.com.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
